Azienda USL IRCCS Di Reggio Emilia
- Address
- Via Giovanni Amendola 2, 42122 Reggio Emilia, Italy
Hematologic Malignancies and Lymphoma Research
At Azienda USL IRCCS Di Reggio Emilia, the Hematology Unit is actively involved in studies across hemic and lymphatic diseases and neoplasms, with a strong focus on follicular lymphoma, marginal zone lymphoma, and multiple myeloma. These trials are mainly designed to compare new treatment combinations, refine disease control, and improve outcomes for patients with relapsed, refractory, or newly diagnosed blood cancers.
- Testing targeted and antibody-based treatments for follicular lymphoma and marginal zone lymphoma
- Evaluating new approaches for relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma
- Assessing whether newer therapies can improve response rates and disease control
This research reflects a broad effort to advance more effective and better-tolerated options for complex hematologic cancers.
Solid Tumor Oncology
The site also contributes to oncology research in several solid tumors, including breast cancer, ovarian cancer, cholangiocarcinoma, pancreatic cancer, gastroesophageal adenocarcinoma, renal cell carcinoma, and glioblastoma. These studies are aimed at testing new therapies, confirming treatment benefit in real-world settings, and improving survival or delaying disease progression.
- Studying new treatment options for advanced ovarian cancer and other difficult-to-treat tumors
- Evaluating therapies for metastatic breast cancer and renal cell carcinoma
- Exploring novel approaches for aggressive cancers such as glioblastoma and pancreatic cancer
This work highlights the center’s role in advancing cancer care through trials focused on both newly diagnosed and advanced disease.
Respiratory, Metabolic, and Musculoskeletal Conditions
Clinical research at the site extends beyond cancer into respiratory tract diseases, nutritional and metabolic diseases, and musculoskeletal diseases. Current studies include chronic obstructive pulmonary disease, gout with hyperuricemia, and thrombotic disease, with the goal of improving symptom control, reducing complications, and testing more effective treatment strategies.
- Assessing new options for COPD in patients with frequent exacerbations
- Comparing treatments for gout to better control uric acid levels
- Investigating therapies for proximal deep vein thrombosis to support clot resolution and safety
These studies show a diverse research portfolio that includes chronic inflammatory and vascular conditions alongside oncology.
Precision Treatment and Diagnostic Research
Several trials at Azienda USL IRCCS Di Reggio Emilia are focused on more personalized care, using disease markers and molecular features to guide treatment decisions in colon cancer, breast cancer, and multiple myeloma. The aim is to improve how patients are selected for therapy, strengthen monitoring tools, and evaluate whether targeted treatment strategies can lead to better outcomes.
- Using biomarkers to guide treatment decisions in early breast cancer and colon cancer
- Improving disease monitoring in multiple myeloma
- Supporting more precise and individualized cancer care
This area of research emphasizes the growing role of biomarker-driven trials in modern clinical practice.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 22 therapeutic areas and 15 of 367 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 350 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 78 by active trials.
lock +77 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fondazione Italiana Linfomi Ets14trials
lock +46 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda USL IRCCS Di Reggio Emilia
lock Showing 1 of 249 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN". | Fondazione Radioterapia Oncologica Onlus | Phase II | Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 367 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 22 | Unknown | 2014-03-24 | 2026-07-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.